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INVITED COMMENTARY
Thomas F. O’Donnell Jr, MD, Boston, Mass
O’Brien and associates have shown that hospital net profit for
lower extremity endovascular treatment (EVI) depends on: (1)
patient status—inpatient vs outpatient, (2) site of service deliv-
ery—operating room vs radiology suite, and (3) type of catheter-
based treatment—percutaneous balloon angioplasty (PTA), stents,
or atherectomy. Why are these observations on EVI, particularly of
the femoral-popliteal segment, important? Femoral-popliteal by-
pass has decreased by 6% over the last decade, and by 2009, it will
comprise only 30% of treatment for this segment.1,2 EVI, however,
is projected to increase by 27% by 2009 for the femoral popliteal
segment and represent 70% of treatment. This tectonic shift in
treatment will greatly affect one of a hospital’s top three sources of
revenue and contribution margin—the vascular service.
Although profound differences in practice patterns were de-
scribed among the hospitals studied, their system, cost and revenue
data was lumped together as mean values. One hospital performed
EVI predominantly in the operating room (OR) as an inpatient
over half the time, while EVI was carried out as an outpatient 75%
of the time and predominantly in the radiology suite. This method
of data presentation not only blurs important financial differences
from one hospital to another but also misses an opportunity to
define “best practices” derived from one institution over another.
Hospital revenue. The authors of this study included few
details on revenue and, for example, they failed to provide the
proportion of patients with chronic comorbidities (DRG #553)
and the specific net revenue for this group. Under CMS reimburse-
ment, these secondary diagnoses can provide additional revenue
for an inpatient procedure, which could account for a $4000 to
$5000 difference in reimbursement for an individual case (vs DRG
#554) and obviously influence contribution margin. Outpatient
reimbursements (APC) under CMS are based on individual en-
counters, so that multiple components for more than one service
provided on the same day can be summated for that hospital visit.
For example, crossing a chronic total occlusion to perform a
balloon angioplasty with placement of a stent in the contralateral
common iliac artery is a compilation of six CPT/HCPS codes of
which 37205 (transcatheter placement of an intravascular stent)
accounts for more than one half of the $7577 estimated total
payment. It is imperative that the hospital coders bill for every
component of the service to maximize revenue.
Hospital costs. A disproportionately high proportion (46%)
of EVI was performed in an OR setting, which was related to lack
of access to interventional suites by the surgeons, who performed
the majority of these procedures. As a former Academic Medical
Center CEO, I would cite this finding and its financial conse-
quences as a cautionary tale for hospital administrators, who nego-
tiate separate, exclusive relationships with interventional radiolo-
gists or cardiologists regarding space—these specialists do not own
the interventional suites, they just use hospital space. The surgeon
is forced to use the OR where the cost structure is significantly
higher than that of the radiology suite, because of the higher cost
per minute of an OR vs a radiology suite (space costs) and the
greater number/payment rate of OR personnel. When inpatient
status (38%) is combined with an OR site, inpatient hospital costs
($12,278) are twice that of procedures performed as an outpatient.
Ironically, this inpatient figure for the less invasive EVI is compa-
rable to that for the surgical treatment of a claudication patient
adjusted for inflation to 2005 reported previously by us.3
Although, unfortunately, no individual components of inpa-
tient/outpatient costs are provided,3 obviously device cost was a
prime driver of the total cost of EVI and poor contributionmargins
in this present study. The use of stents (45%) or atherectomy
devices (38%) doubled the direct cost of the procedure, while
multiple stents further escalated the cost. As opposed to the
situation with open vascular surgery where modification of physi-
cian practice helps to reduce the prime drivers of cost-length of
stay, the hospital runs up against the fixed purchase price of the
device, which has been shown in other studies with endovascular
aneurysm repair to negatively influence hospital profit margin.
Finally, level I evidence with appropriate clinical outcomes rather
than the surrogate outcome of patency are conflicting on the
efficacy of stents over PTA, particularly in the femoral popliteal
segment, so that no grade A recommendation can be made.
Justification for the use of atherectomy catheters is even more
murky and clouded by level 5 studies, many of which are con-
ducted by physician advocates and, in some instances, by those
with direct financial interest in the product. The introduction of
new and potentially costly technology into a hospital should be
guided by evidence for its clinical effectiveness and therefore
appropriate use.
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